MS Drug Cost Without Insurance (2026): Aubagio, Tecfidera & Generics

Last updated May 30, 2026 · 13 min read · By Vincent Couey, RxGrab founder

If you take an oral disease-modifying therapy for multiple sclerosis and you do not have insurance, the price tag can look impossible. Brand-name MS drugs are sold as specialty products, and their list prices run into the thousands of dollars per month. The good news, and the whole point of this guide, is that two of the most common oral options now have true generics that cost a tiny fraction of the brand. This page breaks down the real 2026 cash prices for Aubagio, Tecfidera, and their generics, explains why the brand-to-generic gap is so dramatic, and walks through the savings levers that actually serve uninsured and cash-pay patients.

Heads up: every dollar figure below is approximate and time-sensitive. Specialty and discount prices move by pharmacy, ZIP code, and date, so treat each number as a starting point and verify the current price before you fill.

What do MS drugs cost without insurance?

A disease-modifying therapy, or DMT, is a medication that slows the underlying course of MS rather than just easing symptoms. Oral DMTs are the category most people fill at a retail or mail-order pharmacy, and they are where cash prices vary the most. The single fact that matters for your wallet is whether the specific drug your neurologist prescribed has a marketed generic. Where a real generic exists, the cash price collapses. Where it does not, you are exposed to a brand list price that can exceed a typical mortgage payment.

That distinction is sharper in MS than in almost any other disease area, because the drug class spans two very different worlds. On one side sit the older injectable interferons and the newest infused biologics, many of which still have no generic or biosimilar and carry list prices in the tens of thousands of dollars per year. On the other side sit a handful of oral DMTs whose patents have already expired and which now have inexpensive generics. Two of those, teriflunomide and dimethyl fumarate, are the focus of this guide precisely because they are where an uninsured patient can win the most money back. A reader who only learns one thing here should learn this: find out which side of that line your drug falls on, because it determines whether your realistic cash price is roughly thirty dollars or roughly nine thousand.

Here is the practical picture for the two most common oral DMTs and their generics, alongside a couple of everyday reference drugs so you can see how unusual specialty pricing really is. The everyday statin row is there for scale: an ordinary maintenance drug that millions of people take for under ten dollars a month. Hold that number in mind as you read the brand specialty prices, because it shows how far above a normal cash price these drugs sit, and how close to normal their generics actually land once competition exists. All figures are approximate cash-pay prices for a 30-day supply, as of May 30, 2026.

Why are MS drugs priced as specialty drugs?

A specialty drug is a high-cost medication, often used for a chronic or complex condition, that may require special handling, storage, or distribution. Under Medicare Part D the specialty cost threshold reached $950 in monthly ingredient cost for plan years 2024 and 2025, up from $830 in earlier years, according to CMS. Any drug above that line is generally placed on a plan's specialty tier. Oral MS DMTs like Aubagio and Tecfidera clear that bar easily, which is why they are classed and priced as specialty even though you swallow them like an ordinary pill.

Several forces push these prices up. Many MS therapies are biologics or complex molecules that are expensive to manufacture. Some are limited-distribution products that only specific specialty pharmacies are allowed to dispense, which adds handling and accreditation cost. And for the newest agents there is little or no generic or biosimilar competition, so the manufacturer faces no direct price pressure. The oral DMTs in this guide are the exception that proves the rule: once their patents lapsed and true generics entered the market, the cash price fell off a cliff. To understand how specialty distribution and tiering work in more depth, see our Specialty Pharmacy Guide.

It also helps to understand what the specialty tier actually does to a patient who has no insurance at all. The Part D specialty tier is a concept built for insured patients: it sets how a plan shares the cost of an expensive drug. If you have no plan, none of that machinery applies to you. There is no tier, no coinsurance percentage, and no annual out-of-pocket cap protecting you. You simply face the pharmacy's cash price, which for a brand specialty drug tracks closely to the manufacturer's list price. That is why an uninsured MS patient can end up paying more in absolute dollars than an insured one, even though insured patients are the ones the specialty tier was designed to manage. The specialty classification tells you the drug is expensive; it does nothing to make it affordable to someone paying out of pocket.

This is the structural reason the rest of this guide leans so hard on generic substitution and patient assistance. For an insured patient, the conversation is about which tier a drug sits on and what the copay will be. For the cash-pay reader this site is written for, the only conversations that move the number are whether a cheaper equivalent drug exists and whether a program will give the brand away for free. Everything else is noise.

How much does Aubagio cost, and is teriflunomide the same drug?

Aubagio is the brand name for teriflunomide, a once-daily oral pill for relapsing forms of MS. Without insurance, the brand commonly runs $8,000 to $9,300 for a 30-day supply of the 14 mg tablet. That number is real, and it is the figure that pushes many uninsured patients to skip doses they cannot afford.

Skipping or stretching doses to save money is its own danger, and it is worth naming directly because the price pressure makes it tempting. A disease-modifying therapy works by suppressing the disease process over time, so missed doses can undermine the very benefit the drug exists to provide. The point of finding the generic is not just to save money in the abstract; it is to make consistent, uninterrupted treatment affordable so that no one feels forced to choose between paying rent and taking their medication. When the same drug is available for roughly thirty dollars, that choice does not have to exist.

The crucial fact is that Aubagio's patent has lapsed and generic teriflunomide is now widely marketed by multiple manufacturers. A generic is the same active ingredient at the same strength, reviewed by the FDA to be therapeutically equivalent to the brand. With a free discount coupon, generic teriflunomide 14 mg commonly costs around $28 to $40 for a 30-day supply, with GoodRx often near $30 and SingleCare in a similar range. That is a saving of more than 99 percent versus the brand for the identical medicine.

It is worth pausing on how unusual that gap is. For most prescription drugs, the move from brand to generic shaves off perhaps half to four-fifths of the price. Here it removes more than ninety-nine cents of every dollar. The reason is that the brand list price never reflected the cost of making the molecule; it reflected the value of a patent-protected monopoly on a specialty therapy. Once that monopoly ended, competing manufacturers entered, and the price fell to something much closer to the actual cost of production. The pill in the bottle did not change. Only the market around it did.

Because the saving is so large, it is the first thing any uninsured patient on Aubagio should pursue, ahead of coupons, assistance programs, or anything else. A patient paying the brand price out of pocket is spending roughly the cost of a new car every year on a drug that is available, in identical form, for the price of a few restaurant meals. The barrier is almost never that the generic does not exist. It is that the prescription was written for the brand, the pharmacy filled it as written, and no one flagged the substitution. Closing that gap is a single phone call to the prescriber or a single question at the pharmacy counter.

You can confirm that an approved generic exists by looking your drug up in the FDA Orange Book, the official list of approved drug products and their therapeutic equivalents. If your prescription still reads "Aubagio," ask your neurologist or pharmacist to fill it as teriflunomide instead. In most states the pharmacist can substitute the generic automatically unless the prescriber has specifically blocked substitution.

Is there a generic for Tecfidera?

Yes. Tecfidera is the brand name for dimethyl fumarate, a twice-daily oral DMT for relapsing MS, and generic dimethyl fumarate is now marketed by several manufacturers after generic entry. Without insurance, brand Tecfidera runs roughly $7,800 a month. Generic dimethyl fumarate with a coupon commonly lands around $40 to $100 or more for a 30-day supply, with GoodRx cited near $41 at the low end. The exact figure varies more than teriflunomide does, so it is worth comparing several pharmacies.

You may also see a separately marketed low-cost dimethyl fumarate option advertised at a fixed pharmacy price, sometimes described as around $47 in pharmacy cost with a capped patient cost near $68. Treat those specific dual figures with caution: we could not independently re-verify the exact $47 and $68 numbers in this pass, so confirm the program and its current terms directly before you rely on them. The dependable takeaway is broader: a marketed generic exists, and it costs a small fraction of the brand.

One practical wrinkle with dimethyl fumarate is that it is taken twice a day and is sometimes titrated, meaning the dose is stepped up over the first weeks of treatment. That matters for budgeting because a starter pack or a lower-strength fill may be priced differently from the maintenance dose, and the per-month cost you see quoted online usually reflects the steady-state maintenance supply. When you compare prices, make sure you are comparing the same strength and the same day count. A coupon that looks unusually cheap may be for a smaller quantity, and a quote that looks high may bundle a titration pack. As always, the figure that matters is the out-the-door price for your exact prescription at your exact pharmacy, which only a real quote will give you.

The broader point holds across both drugs in this guide. Whether your prescription reads Aubagio or Tecfidera, the brand is a four-figure monthly bill and the generic is a two-figure one. The work for an uninsured patient is not hunting for an exotic discount on the brand. It is making sure the prescription is filled as the generic in the first place, then shopping that generic across a few pharmacies to shave the last few dollars.

Why do manufacturer copay cards not help the uninsured?

A copay card, sometimes called a copay savings program, is a manufacturer offer that lowers what you pay at the pharmacy counter for a brand drug. They are heavily advertised, and on a brand specialty MS drug they can look like the obvious answer. For uninsured and cash-pay patients, they usually are not.

The reason is buried in the fine print. Manufacturer copay cards almost always require commercial or private insurance and explicitly exclude cash-pay, uninsured, and government-insured patients, meaning anyone on Medicare or Medicaid. If you have no insurance, you typically do not qualify at all. This is the single most common trap for the audience this guide is written for, so it is worth stating plainly: a copay card is not a cash-pay discount. Do not build your plan around one if you are uninsured.

Why are copay cards built this way? They exist to lower a patient's share of the cost while the insurer still pays the bulk of the bill. The manufacturer is effectively buying down the copay so that the patient stays on the brand rather than switching to a cheaper alternative. That math only works when there is an insurer covering most of the price. For an uninsured patient there is no insurer to cover the rest, so the program has no economic logic and the terms exclude you. Federal rules also bar these cards for Medicare and Medicaid beneficiaries, which is why government-insured patients are shut out even though they technically have coverage. None of this is hidden malice; it is simply that the tool was never designed for the cash-pay buyer.

So what does serve the uninsured? Patient assistance programs, or PAPs, are a different animal. These manufacturer- or foundation-run programs provide free or low-cost medication to qualifying low-income and uninsured patients, and unlike copay cards they can serve cash-pay payers, subject to income eligibility. For a high-cost brand specialty drug where no affordable generic exists, a PAP is often the best route. Our Patient Assistance Programs Guide walks through how to find and apply to them.

The contrast between the two programs is worth memorizing because it is the most common point of confusion in prescription savings. A copay card lowers your share of a bill that an insurer is mostly paying, and it requires that insurer. A patient assistance program gives a drug to someone who cannot pay for it at all, and it is built for the uninsured and underinsured. They sound similar and are often advertised on the same manufacturer page, but they point in opposite directions. If you are the cash-pay reader this site exists for, the copay card is almost always a dead end and the assistance program is almost always the door worth knocking on. The catch is that PAPs ask for documentation, usually proof of income and residency, and they take time to approve, so it is wise to apply well before you run out of medication rather than at the last moment.

Which savings levers actually work for cash-pay patients?

Not every advertised discount applies to someone paying out of pocket. A lot of prescription-savings advice is written for people who have insurance and are trying to lower a copay, which is a different problem from having no coverage at all. The list below is ordered specifically for the uninsured and cash-pay reader, with the levers that move the most money placed first and the ones that rarely help that audience placed last. The ordering itself is the advice: spend your time at the top of the list, not the bottom.

1. Generic substitution. Where a true marketed generic exists (teriflunomide, dimethyl fumarate), this is the single largest lever, often more than 99 percent savings versus the brand. Always check the FDA Orange Book first.
2. Discount coupons. Free, cash-pay, and no insurance needed. GoodRx and SingleCare deliver the biggest wins on generics. Prices vary by pharmacy and ZIP, so compare a few before you fill.
3. Cost Plus Drugs. Mark Cuban Cost Plus Drugs uses transparent pricing: manufacturer cost plus a 15 percent markup plus a pharmacy fee plus shipping. It is strong for established generics, but it cannot help where no generic exists or for limited-distribution biologics. Read our Cost Plus Drugs review for the full breakdown.
4. Patient assistance programs. The best lever for high-cost brand specialty drugs with no affordable generic. Subject to income limits, but they can serve uninsured and cash-pay patients.
5. 90-day supplies. For chronic maintenance drugs, a 90-day fill lowers per-month cost and reduces dispensing fees.
6. Copay cards. Last on this list on purpose: they generally exclude the uninsured and cash-pay patients. Useful only if you have commercial insurance.

The chart below puts the brand-versus-generic gap for the two MS drugs in this guide into one view. It is built from the same approximate 2026 cash-pay figures used in the price table above.

How do you actually pay less for an MS drug without insurance?

If you are uninsured, here is the practical sequence that saves the most money, in order.

1. Confirm whether your brand has a true generic. Look your drug up in the FDA Orange Book. Teriflunomide and dimethyl fumarate have marketed generics; many MS injectables and biologics do not.
2. Ask your prescriber for the generic by its chemical name. Request teriflunomide instead of Aubagio, or dimethyl fumarate instead of Tecfidera, so the pharmacy fills the lower-cost equivalent.
3. Compare cash prices with coupons. Check GoodRx, SingleCare, and Cost Plus Drugs for the generic at pharmacies near you. Prices vary, so a few minutes of comparison can cut your bill further.
4. Consider a 90-day supply. For a chronic medication, buying in bulk lowers your per-month cost and dispensing fees.
5. Apply for a patient assistance program if no affordable generic exists. For brand-only specialty drugs, a manufacturer or foundation PAP can provide the drug free or at low cost to qualifying uninsured patients. Start with our Patient Assistance Programs Guide.

A few realistic expectations help here. Switching from a brand to a generic is usually quick, because the pharmacist can often substitute at the counter the same day. Comparing coupons takes a few minutes and pays for itself immediately. Cost Plus Drugs and other mail-order options add shipping time, so plan for a few days of buffer on your supply. Patient assistance programs are the slowest path, sometimes taking weeks to approve, which is exactly why they should be started early rather than treated as an emergency fix. None of these steps requires insurance, a broker, or a fee. Anyone advertising a paid service to do this for you is charging you for something you can do yourself for free.

What about MS drugs that still have no generic?

Not every MS therapy has an affordable equivalent, and it is important to be honest about that. Many injectable and infused DMTs, including several widely used biologics, remain brand-only with no generic or biosimilar on the U.S. market. For those drugs the levers in this guide work differently. Generic substitution is simply not available, discount coupons make little dent in a five-figure annual price, and Cost Plus Drugs does not carry limited-distribution biologics. The realistic path for an uninsured patient on one of those therapies is the patient assistance program, supported where possible by independent charitable foundations that help with specialty-drug costs.

This is why the very first step in the how-to sequence is to confirm, in the FDA Orange Book, whether your specific drug has an approved generic. The answer reshapes your entire strategy. If it does, the generic plus a coupon is the whole game and you will likely pay double digits. If it does not, you should pivot immediately to assistance programs and not waste time hunting for a coupon that cannot meaningfully move a biologic's price. Knowing which situation you are in is the difference between a plan that works and weeks of frustration chasing discounts that do not apply to your drug.

It is also worth raising the cost question with your neurologist directly. Prescribers do not always know what a given drug costs a cash-pay patient, and they often have flexibility about which therapy in a class to choose when more than one would be clinically reasonable. A patient who says plainly that they are uninsured and need the most affordable effective option is giving the prescriber information they cannot get any other way. That conversation, combined with an Orange Book check and a coupon comparison, is the most powerful thing an uninsured MS patient can do, and it costs nothing but the willingness to ask.

Glossary

Disease-modifying therapy (DMT)

A medication that slows the underlying course of multiple sclerosis rather than only treating symptoms. Aubagio and Tecfidera are oral DMTs.

Specialty drug

A high-cost medication for a chronic or complex condition that may require special handling or distribution. Under Medicare Part D the specialty cost threshold was $950 per 30-day ingredient cost for 2024 and 2025.

Generic

A drug with the same active ingredient and strength as a brand, reviewed by the FDA to be therapeutically equivalent. Teriflunomide is the generic of Aubagio; dimethyl fumarate is the generic of Tecfidera.

Copay card

A manufacturer program that lowers the counter price of a brand drug, but one that almost always requires commercial insurance and excludes cash-pay, uninsured, Medicare, and Medicaid patients.

Patient assistance program (PAP)

A manufacturer- or foundation-run program that provides free or low-cost medication to qualifying low-income or uninsured patients. Unlike copay cards, PAPs can serve cash-pay payers.

FDA Orange Book

The official FDA publication listing approved drug products and their therapeutic equivalents. Use it to confirm whether a true generic of your drug exists.

Frequently asked questions